A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

Eli Lilly has spent the last several years reintroducing itself to the public via a series of corporate campaigns. | Eli Lilly has spent the last several years reintroducing itself to the public via a ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, according to its chief corporate brand officer Lina Polimeni.

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a ...

President Donald Trump's second term in office has been challenging for investors, at least so far. Trump imposed sweeping ...